By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree
POSTERS

LUM-201

ENDO 2021

LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency

ENDO 2021 Poster Presentation by Author George Bright, MD
(video and poster below)

Session P33 – Growth and Growth Hormone

March 20, 2021

Authors

George Bright, MD, Roy Smith, PhD, Michael O. Thorner, MB, BS, DSc.
Lumos Pharma, Austin, TX, USA.

Disclosures

G. Bright: Consulting Fee; Self; Lumos Pharma. R. Smith: Consulting Fee; Self; Lumos Pharma. M.O. Thorner: Consulting Fee; Self; Lumos Pharma. Stock Owner; Self; Lumos Pharma.

Abstract

Abstract Title: “LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency “Presentation Type: OralScience Type and Topic: Clinical Trial Introduction: LUM-201 (ibutamoren, formerly MK-0677) is an orally administered GH-secretagogue that stimulates the GH secretagogue receptor (GHSR1a) in the hypothalamus and pituitary. LUM-201 is in development for long-term use in a subset of PGHD patients with moderate growth deficiencies. A diagnosis of PGHD is confirmed by low GH responses to standard GH secretagogues (clonidine, arginine, L-dopa, glucagon, insulin) so it is somewhat counter-intuitive to suggest that children who cannot respond to one GH secretagogue might have favorable responses to LUM-201. Objective: To determine if LUM-201 stimulates GH responses differently than standard GH secretagogues. Methods: 68 naïve-to-treatment, prepubertal children with GHD received two standard GH stimulation tests and a test with a single 0.8 mg/kg dose of LUM-201. The 68 subjects included 20 girls and 48 boys. The median (interquartile range) age was 9.2 years (7.2,10.8), bone age 6.0 years (4.5, 7.9), height SDS -3.3 (-4.5, -2.5), pretreatment height velocity 4.0 cm/y (3.2, 4.6), and baseline IGF-1 51 ng/mL (24,111). Results: The median (interquartile range) of maximal GH response to single dose LUM-201 was 15.0 ng/mL (3.5, 49) and to various pairs of standard stimuli was 5.4 ng/mL (1.8-7.6) (p< 0.00001). The median (IQR) for the difference between GH responses to LUM-201 and standard stimuli was 9.6 ng/ml (1.9, 42). In a multivariate analysis (r2 =0.73) differential GH increased with higher values of baseline IGF-I (p < 0.00001) and standard GH stimulation test (p = 0.047) but was not influenced by age (p = 0.16), sex (p = 0.28), baseline HV (p = 0.24), age-bone age differences (p = 0.33) or height-SDS (p = 0.75) . Conclusion: In GHD children, the GH response to single-dose LUM-201 greatly exceeds that observed with standard GH testing agents. The difference is greatest among patients with higher baseline values of IGF-I and higher GH responses to standard stimuli. The synergistic actions of LUM-201 on the physiological mechanisms regulating GH release explain why GH responses are greater in response to LUM-201 compared to traditional tests used to diagnose PGHD.

 

 

 

View the Poster

LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency

PUBLICATIONS

LUM-201

 

Development of a Predictive Enrichment Marker for Oral GH Secretagogue LUM-201 in Children with Growth Hormone Deficiency

    • George M Bright, MD
    • Minh-Ha T Do, PhD
    • John C McKew, PhD
    • Werner F Blum, MD
    • Michael O Thorner, MB, BS, DSc

Journal of the Endocrine Society – bvab030
Published:  25 February 2021

 

Corroboration of Height Velocity Prediction Markers for rhGH with an Oral GH Secretagogue Treatment in Children with GHD

    • Werner F Blum, MD
    • George M Bright, MD
    • Minh-Ha T Do, PhD
    • John C McKew, PhD
    • Haiying Chen, MD, PhD
    • Michael O Thorner, MB, BS, DSc

Journal of the Endocrine Society – bvab029
Published:  25 February 2021